Document is current
Any future updates will be listed below
-
Authors
Conroy, S. https://orcid.org/0000-0001-7167-4908
Gagg, H.
Quayle, LA https://orcid.org/0000-0002-6394-4186
Adams, JA
Williams, ST
Helleday, T.
Hussain, SA https://orcid.org/0000-0003-1552-511X
Griffin, J. https://orcid.org/0000-0003-3969-7637
Allen, R.
Rantala, JK https://orcid.org/0000-0002-4999-5585
Danson, SJ https://orcid.org/0000-0002-3593-2890
Catto, JWF
Wells, G. https://orcid.org/0000-0002-1337-9836
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 7 April 2026
First Online: 14 May 2026
Competing interests
: S.C. has received speaker fees from InMed. S.A.H has received research funding from Cancer Research UK, MRC/NIHR, UHB charities, CCC charities, North-West Cancer Research, Yorkshire Cancer Research, Weston Park Cancer Charity, Bayer, Janssen, Boehringer Ingelheim, Pierre Fabre, Eli Lilly, Roche, and has received advisory board/consultancy fees from Roche, MSD, AstraZeneca, BMS, Janssen, GSK, Astellas, Pfizer, Bayer, Merck, Pierre Fabre, Sotio, Gilead. JG has received research funding from Roche and in-kind research support from Owkin and has received honoraria from ISSECAM. JKR is the founder of Misvik Biology Ltd and has received research funding from AstraZeneca and Boehringer Ingelheim. SJD has received consulting fees from Orion Therapeutics, Oxcia and Incanthera. JWFC has received consulting fees from AstraZeneca, Ferring, Ipsen, Roche, and Janssen; has received speaker fees from Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Janssen, Astellas, Nucleix, InMed, and Roche; has received honoraria for membership in advisory boards from Ferring, Roche, Gilead, Photocure, Pfizer, Bristol Myers Squibb, QED Therapeutics, and Janssen; and has received research funding from Roche. HG, LAQ, STW, TH, RA, and GW have declared no conflicts of interest.
